Sirtuins: Novel targets for metabolic disease in drug development

Biochemical and Biophysical Research Communications

Volumn 373, Issue 3, 2008, Pages 341-344

  Jiang, Wei jian ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Resveratrol; Sirtuins

Indexed keywords

INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RESVERATROL; SIRTUIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FOXO;

BULIMIA; CALORIC INTAKE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; FRUIT JUICE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; INSULIN RELEASE; LIFESPAN; METABOLIC DISORDER; NONHUMAN; OBESITY; POLYDIPSIA; PRIORITY JOURNAL; RED WINE; SHORT SURVEY; STREPTOZOCIN DIABETES; WEIGHT REDUCTION;

ANIMALS; ANTIOXIDANTS; CALORIC RESTRICTION; DIABETES MELLITUS; DRUG DESIGN; ENZYME ACTIVATION; HUMANS; INSULIN; MALE; MICE; RATS; SIGNAL TRANSDUCTION; SIRTUINS; STILBENES; SUBSTRATE SPECIFICITY;

MUS;

EID: 47249108032     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.06.048     Document Type: Short Survey

References (57)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Zierath J.R., He L., Guma A., Odegoard Wahlstrom E., Klip A., and Wallberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39 (1996) 1180-1189
3. Saltiel A.R. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104 (2001) 517-529
4. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., and Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
5. McCay C.M., Crowell M.F., and Maynard L.A. The effect of retarded growth upon the length of life span and upon the ultimate body size, 1935. Nutrition 5 (1989) 155-171 discussion 172
6. Rine J., and Herskowitz I. Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics 116 (1987) 9-22
7. Lin S.J., and Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell Biol. 15 (2003) 241-246
8. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., and Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123 (2005) 437-448
9. Leibiger I.B., and Berggren P.O. Sirt1: a metabolic master switch that modulates lifespan. Nat. Med. 12 (2006) 34-36 discussion 36
10. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., and Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003) 191-196
11. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., and Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430 (2004) 686-689
12. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., and Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006) 337-342
13. Miller E.S., Heidelberg J.F., Eisen J.A., Nelson W.C., Durkin A.S., Ciecko A., Feldblyum T.V., White O., Paulsen I.T., Nierman W.C., Lee J., Szczypinski B., and Fraser C.M. Complete genome sequence of the broad-host-range vibriophage KVP40: comparative genomics of a T4-related bacteriophage. J. Bacteriol. 185 (2003) 5220-5233
14. Imai S., Armstrong C.M., Kaeberlein M., and Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 (2000) 795-800
15. Landry J., Sutton A., Tafrov S.T., Heller R.C., Stebbins J., Pillus L., and Sternglanz R. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA 97 (2000) 5807-5811
16. + dependent protein deacetylase activity in the Sir2 protein family. Proc. Natl. Acad. Sci. USA 97 (2000) 6658-6663
17. Hernick M., and Fierke C.A. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch. Biochem. Biophys. 433 (2005) 71-84
18. Marmorstein R. Structure of histone deacetylases: insights into substrate recognition and catalysis. Structure 9 (2001) 1127-1133
19. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434 (2005) 113-118
20. Bordone L., Motta M.C., Picard F., Robinson A., Jhala U.S., Apfeld J., McDonagh T., Lemieux M., McBurney M., Szilvasi A., Easlon E.J., Lin S.J., and Guarente L. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol. 4 (2006) e31
21. Moynihan K.A., Grimm A.A., Plueger M.M., Bernal-Mizrachi E., Ford E., Cras-Meneur C., Permutt M.A., and Imai S. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2 (2005) 105-117
22. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776
23. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., and Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305 (2004) 390-392
24. Pilkis S.J., and Granner D.K. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu. Rev. Physiol. 54 (1992) 885-909
25. Owen O.E., Kalhan S.C., and Hanson R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277 (2002) 30409-30412
26. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 282 (2007) 34356-34364
27. Dhahbi J.M., Mote P.L., Wingo J., Tillman J.B., Walford R.L., and Spindler S.R. Calories and aging alter gene expression for gluconeogenic, glycolytic, and nitrogen-metabolizing enzymes. Am. J. Physiol. 277 (1999) E352-E360
28. Hagopian K., Ramsey J.J., and Weindruch R. Caloric restriction increases gluconeogenic and transaminase enzyme activities in mouse liver. Exp. Gerontol. 38 (2003) 267-278
29. Hobbs H.H., Russell D.W., Brown M.S., and Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24 (1990) 133-170
30. Conkright M.D., Canettieri G., Screaton R., Guzman E., Miraglia L., Hogenesch J.B., and Montminy M. TORCs: transducers of regulated CREB activity. Mol. Cell 12 (2003) 413-423
31. Lin J., Yang R., Tarr P.T., Wu P.H., Handschin C., Li S., Yang W., Pei L., Uldry M., Tontonoz P., Newgard C.B., and Spiegelman B.M. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120 (2005) 261-273
32. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., and Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413 (2001) 179-183
33. Bluher M., Kahn B.B., and Kahn C.R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299 (2003) 572-574
34. Michan S., and Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 404 (2007) 1-13
35. Yang T., Fu M., Pestell R., and Sauve A.A. SIRT1 and endocrine signaling. Trends Endocrinol. Metab. 17 (2006) 186-191
36. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., and Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16 (2004) 93-105
37. Lerin C., Rodgers J.T., Kalume D.E., Kim S.H., Pandey A., and Puigserver P. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 3 (2006) 429-438
38. Rodgers J.T., and Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. USA 104 (2007) 12861-12866
39. Tran H., Brunet A., Griffith E.C., and Greenberg M.E. The many forks in FOXO's road. Sci. STKE 2003 (2003) RE5
40. Accili D., and Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117 (2004) 421-426
41. van der Horst A., and Burgering B.M. Stressing the role of FoxO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 440-450
42. Huang H., and Tindall D.J. Dynamic FoxO transcription factors. J. Cell Sci. 120 (2007) 2479-2487
43. Barthel A., Schmoll D., and Unterman T.G. FoxO proteins in insulin action and metabolism. Trends Endocrinol. Metab. 16 (2005) 183-189
44. Hwangbo D.S., Gershman B., Tu M.P., Palmer M., and Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 429 (2004) 562-566
45. Zhang W., Patil S., Chauhan B., Guo S., Powell D.R., Le J., Klotsas A., Matika R., Xiao X., Franks R., Heidenreich K.A., Sajan M.P., Farese R.V., Stolz D.B., Tso P., Koo S.H., Montminy M., and Unterman T.G. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281 (2006) 10105-10117
46. Kamei Y., Miura S., Suzuki M., Kai Y., Mizukami J., Taniguchi T., Mochida K., Hata T., Matsuda J., Aburatani H., Nishino I., and Ezaki O. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J. Biol. Chem. 279 (2004) 41114-41123
47. Watamoto K., Towatari M., Ozawa Y., Miyata Y., Okamoto M., Abe A., Naoe T., and Saito H. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. Oncogene 22 (2003) 9176-9184
48. Nakae J., Biggs III W.H., Kitamura T., Cavenee W.K., Wright C.V., Arden K.C., and Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat. Genet. 32 (2002) 245-253
49. Matsumoto M., Han S., Kitamura T., and Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 116 (2006) 2464-2472
50. Castrillon D.H., Miao L., Kollipara R., Horner J.W., and DePinho R.A. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301 (2003) 215-218
51. Lemieux M.E., Yang X., Jardine K., He X., Jacobsen K.X., Staines W.A., Harper M.E., and McBurney M.W. The Sirt1 deacetylase modulates the insulin-like growth factor signaling pathway in mammals. Mech. Ageing Dev. 126 (2005) 1097-1105
52. Aoyama H., Daitoku H., and Fukamizu A. Nutrient control of phosphorylation and translocation of Foxo1 in C57BL/6 and db/db mice. Int. J. Mol. Med. 18 (2006) 433-439
53. Stapleton D., Woollatt E., Mitchelhill K.I., Nicholl J.K., Fernandez C.S., Michell B.J., Witters L.A., Power D.A., Sutherland G.R., and Kemp B.E. AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett. 409 (1997) 452-456
54. Su H.C., Hung L.M., and Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E1339-E1346
55. Backesjo C.M., Li Y., Lindgren U., and Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 21 (2006) 993-1002
56. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006) 1109-1122
57. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., and Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450 (2007) 712-716